|
|
ClopidogrelThis cost-effectiveness analysis in patients undergoing pci confirms that clopidogrel on top of standard therapy including asa acetylsalicylic acid ; compares very well with other treatments in cardiovascular medicine, said dr. A NEW study has linked a combination of aspirin and the antiplatelet agent clopidogrel with life-threatening bleeds in high-risk stroke patients. The study also showed no additional clinical benefit with the aspirin clopidogrel combination. The major health threat to patients who have suffered an initial ischaemic stroke IS ; or transient ischaemic attack TIA ; is a second stroke. The risk of a recurrence is high -- up to 14% annually.A stroke patient is up to fives times more likely to suffer a second stroke than a myocardial infarction. Aspirin has long been established to reduce the risk of second stroke and the combination of aspirin with dipyridamole MR Asasantin Retard ; doubles this protective effect compared with placebo, relative risk of second stroke is reduced by 18% with aspirin and 37% with dipyridamole MR plus low dose aspirin ; . However, results of the MATCH trial Management of AtheroThrombosis with Cloidogrel in High risk patients ; reported at the 13th European Stroke Conference in Mannheim, show that in high risk patients with recent IS or TIA, the combination of aspirin 75mg daily with clopidogrel 75mg daily shows no beneficial clinical effects and doubles the risk of a life-threatening bleed which includes intracranial bleeding ; . For further information please contact KWT Public Relations Ltd, Tel. 0208 541 5999, E-Mail. enquiries.kwt blueyonder. Although all of these drugs are absorved following intramuscular injection, they are usually given intravenously because of the pain associated with intramuscular administration. Trial ; 35 that aspirin given within 48 hours of a stroke seems to reduce mortality and rate of recurrent stroke minimally, but statistically significantly. Whether the mild positive effect of early aspirin treatment is due to an effect on the infarct itself or to prevention of recurrent infarction is not yet clear. Aspirin has anti-inflammatory actions as well as antiplatelet effects and it is not known to what extent these properties are involved. Aspirin can be given soon after an acute stroke when a CT scan or MRI scan is unavailable, since in the IST few patients who were later shown to have cerebral haemorrhage appeared to come to significant harm. Whether antiplatelet drugs other than aspirin such as dipyridamole and clopidogrel ; are indicated in the acute phase after acute ischaemic stroke is not known36, 37. The ongoing PRoFESS Prevention Regimen for Effectively Avoiding Second Strokes ; study has recently dropped its clopidogrel + aspirin arm, following the results of the MATCH Management of ATherothrombosis with Cloidogrel in High-risk patients with recent TIA or ischemic stroke ; trial, in which this combination was found to be ineffective and even harmful bleeding ; in secondary prevention. PRE PROCEDURE MEDICATION RECOMMENDATIONS This applies to you if you are taking a medication that "thins your blood." YOU MUST obtain medical clearance to discontinue medication from your Primary Care Practitioner, AND then stop the medication before the Pain Procedure as follows: 1 ; ASPIRIN & ASPIRIN CONTAINING PRODUCTS: a ; May continue taking as prescribed unless specifically instructed by your pain physician 2 ; COUMADIN WARFARIN ; : a ; STOP 5 days before your appointment. b ; Go to the lab at least one day before your appointment time to have your blood drawn. c ; Contact Coumadin Clinic that assist you in obtaining medical clearance and for full instructions regarding going off and back on your Coumadin. 3 ; PLAVIX CLOPIDOGREL ; or PLETAL CILOSTAZOL ; or PERSANTINE DIPYRIDAMOLE ; : a ; STOP 7 days before your appointment. b ; YOU ARE RESPONSIBLE to contact you Primary Care Provider for medical clearance to stop this medication. c ; You DO NOT need to have any blood drawn before the pain procedure. 4 ; TICLOPIDINE TICLID ; a ; STOP 10 days before your appointment. b ; YOU ARE RESPONSIBLE to contact you Primary Care Provider for medical clearance to stop this medication. c ; You DO NOT need to have any blood drawn before the pain procedure 5 ; NSAIDS NON-STEROIDAL ANTI-INFLAMATORY DRUGS ; : a ; May continue taking as prescribed unless specifically instructed by your pain physician 6 ; LEVONOX FRAGMIN ARIXTRA: a ; DO NOT take for 24 hours before your pain procedure. 7 ; HIGH BLOOD PRESSURE, HEART MEDICATIONS AND BLOOD SUGAR MEDICATIONS: a ; Most of these medications should be continued unless specifically instructed. Please inform your doctor about these medications. 8 ; PAIN MEDICATIONS: a ; Pain medications may be continued to the day of procedure and taken with a sip of water. Hong Kong Doctors Union Nutrition Supplements: What's Hot and What's Fact Video Cassette Session ; 1 Room 901, Hang Shing Bldg, 363-373, Nathan Road, Kln The Federation of Medical Societies of Hong Kong & The Hong Kong Thoracic Society Ltd & American College of Chest Physicians 1.5 HK and Macau Chapter ; Certificate Course in Respiratory Medicine Session 4 Sleep Related Breathing Disorder: An Update Room 204, Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, HK 20 Oct 2005 Hong Kong Poison Information Centre Thur ; Monthly Meeting of Hong Kong Poison Information Centre 2 -- 2 10: 00 12: 00 noon United Christian Hospital 20 Oct 2005 HKMA CME Programme Thur ; Office Dermatology 1 00 The Ballroom, Level 2, Langham Hotel Hong Kong, 8 Peking Road, TST 20 Oct 2005 HK College of Community Medicine: PHM-Review Meeting Thur ; Review Meetings in areas related to Public Health Medicine 2 6: 00 Chung House, Wanchai 21 Oct 2005 HKMA-Sha Tin Doctors Network Fri ; Advanced Atopic Dermatitis Treatment 1 30 Seminar Room, 2 F, Medical Centre, Union Hospital, Shatin 21 Oct 2005 Union Hospital Fri ; Minimally invasive thoracic surgery current status and future prospects 1 2: Seminar Room, 2 F, Medical Centre, Union Hospital 21 Oct 2005 The Hong Kong Medical Association Fri ; An Introduction to the Patient Complaints Mediation Committee PCMC ; 1.5 2: 00 3: HKMA The HKMA Dr. Li Shu Pui Professional Education Centre 21 Oct 2005 HKU Centre on Behavioral Health Fri ; Therapy in the Satir Model Advanced Professional Course for Practitioners 3 6: 30 Centre on Behavioral Health, The University of Hong Kong, G F Pauline Chan Building, 10 Sassoon Road, Pokfulam 21 23 Oct 2005 International Academy of Pathology, Hong Kong Division HKIAP ; Fri Sun ; 14th Annual Scientific Meeting of HKIAP Surgical Pathology Update 2005 10# 9: 00am 5: 00 Postgraduate Education Center, Prince of Wales Hospital 21 23 Oct 2005 Hong Kong College of Radiologists Fri Sun ; Joint Scientific Meeting of The Royal College of Radiologists & 10# 15# -- 8# 10# Hong Kong College of Radiologists and 13th Annual Scientific Meeting of Hong Kong College of Radiologists Hong Kong Academy of Medicine Jockey Club Building 22 Oct 2005 HA HKCCM Sat ; Case presentations and journal presentations in areas related to 3 9: noon Administrative Medicine Seminar Room 1, M F, Hospital Authority Building 22 Oct 2005 CUHK Department of Social Work, Kwai Chung Hospital Sat ; Yaumatei Child & Adolescent Psychiatric Centre 10# 9: Integrated Training Course on Childhood and Adolescent Disorders Session 2 ; SWC LT1, Lecture Theatre, Shaw College, CUHK 22 Oct 2005 HKMA CME Programme Sat ; Exercise Prescription Certification Course Session 1 ; : 2.5 1: 00 4: Module 1 Introduction Module 2 How to Write an Exercise Prescription I ; Lecture Theatre, Block P, United Christian Hospital 22 Oct 2005 HKU HKU Family Institute Sat ; Certificate Course in Family Therapy Level 1 Session 5 ; 3 2: Lecture Hall, HKU Family Institute, 5 F Tsan Yuk Hospital, 30 Hospital Road, Sai Ying Pun, HK 22 Oct 2005 Social Hygiene Service, PHSB, CHP, DH Sat ; Interactive STI Sexually Transmitted Infections ; Workshop for clinicians 2005 2 Cheung Sha Wan Dermatological Clinic, 3 F West Kowloon Health Centre, 303 Cheung Sha Wan Road, Shamshuipo, Kowloon 23 Oct 2005 CUHK Department of Medicine & Therapeutics, Department of Sun ; Paediatrics, DH Centre for Health Protection, the Social Hygiene Service 7 6 2nd CUHK Dermatology Symposium Kowloon Shangri-La Hotel Hong Kong ; 23 Oct 2005 Sun Yat-Sen University of Medical Sciences, HK Alumni Association Sun ; Conjunctivitis, red eye, dry eye 1.5 1: 00 3: HKMA Dr. Li Shu Pui Professional Education Center, 2 F, 21 Connaught Road, Hong Kong 23 Oct 2005 CUHK Dept of Medicine & Therapeutics Sun ; CUHK Diploma Programme in Advanced Internal Medicine 2004-05 3 15# Geriatric problems Plaza Conference Centre, 35 F Central Plaza, 18 Harbour Road, HK 23 Oct 2005 CUHK Dept of Medicine & Therapeutics Sun ; CUHK Diploma Programme in Advanced Internal Medicine 2004-05 3 15# 00 8: 00 Cold and influenza Plaza Conference Centre, 35 F Central Plaza, 18 Harbour Road, HK 24 Oct 2005 HA Tuen Mun Hospital, Internal Medicine Dept Mon ; Use of Mabthera in local Chinese patients with NHL 1 5: 00 D1002, 1 F, Main Block and cloxacillin. NHS Direct Pilots are set up. NHS Modernisation teams established. NHS Direct Self-help Guide is published. Seek medical attention right away if any of these severe side effects occur: severe allergic reactions rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue abdominal or stomach pain or tenderness; blurred vision; changes in sexual ability such as impotence or ejaculation problems dark urine; difficulty urinating; pale stools; severe headache; tremors; unexplained flu-like symptoms; unusual fatigue or tiredness; unusually fast heartbeat; weight loss; yellowing of skin or eyes and cromolyn, because clopidogrel active metabolite. Property; to the extent any generalization can be made, "increased therapeutic activity is normally accompanied by increased toxicity." Id. at 755. But that was not true of levofloxacin; it was both more active and less toxic than racemic ofloxacin which, again, unlike PCR 4099, was a marketed drug ; . Id. at 754. This same general correlation between activity and toxicity was also unexpectedly and favorably absent with clopidogrel. With clopidogrel, the split between toxicity and activity was surprisingly sharp: clopidogrel was effective in inhibiting platelets, but never caused convulsions in any animal or, man, for that matter, so far as is known ; , whereas the levorotatory enantiomer of PCR 4099 had neurotoxic potential and no antiplatelet activity. c. Lipitor. Coronary artery stenting has definitely been proven to improve results of percutaneous revascularisation in a large number of patients. Stenting reduces restenosis in large vessels above 3 mm diameter. Stenting has not solved the problem of restenosis but in spite of the inevitable in-stent restenosis due to neointimal proliferation seems to yield better long-term results than conventional PTCA. Adjunctive pharmacological treatment with aspirin and clopidogrel in combination with improved stent deployment techniques has reduced the incidence of subacute stent thrombosis. GP IIb IIIa inhibition is a promising mean for the reduction of procedure related ischaemic events and complications not only with stent implantation but also with conventional PTCA. Other new devices may further influence the treatment choices of stenting versus conventional PTCA in the future. Novel approaches such as brachytherapy and molecular genetic approaches to reduce in-stent restenosis are currently being investigated but to date no conclusions can be drawn as to their future place in clinical practice. From a mechanistic standpoint it seems obvious to give all our efforts to protect patients with coronary atherosclerosis from loss of myocardium either with coronary artery bypass grafting or percutaneous revascularisation. As both approaches are palliative in nature, it may be useful to attempt percutaneous revascularisation in patients amenable to this therapy and thus obviate or delay the need for definitive revascularisation by coronary artery bypass grafting. At the end of this discussion we would like to remind that medical therapy for coronary artery disease is of utmost importance as all revascularisation procedures do not influence the underlying disease. Besides symptomatic relief of angina, treatment of heart failure, and other beneficial strategies to improve endothelial function, medical therapy with lipid lowering compounds together with risk factor control offers the possibility to delay progression of coronary artery disease. Keywords: stent; coronary angioplasty and danocrine. Compared with placebo. Extrapolating from this to the CAPRIE study[12], clopidogrel prevents 24 similar events per year per 1000 patients. A possibly comparable figure for statins could come from a study of simvastatin for secondary prevention conducted in more that 4000 patients[4], in which treatment would prevent approximately 20 events per year per 1000 patients on therapy. Similarly, a recent meta-analysis of antihypertensive therapy in the elderly[14] showed that this avoided 14 events per year per 1000 patients treated. The magnitude of the benefit of these very different approaches appears to be of the same order; the benefits are also probably additive. Prefer semiautomatic devices rather than a mercury sphygmomanometer to avoid the difficulty posed by having to educate the patient on its use and the error derived from hearing problems in elderly individuals. Instruct the patient to make measurements in the sitting position after several minutes rest, preferably in the morning and in the evening. Inform him or her that values may differ between measurements because of spontaneous blood pressure variability. Avoid requesting that an excessive number of values are measured and ensure that those measurements include the period prior to drug intake so as to have information on the duration of treatment effects. Remember that, as for ambulatory blood pressure, normal values are lower for home than for office blood pressure. Take 130135 85 mmHg as the values that approximately correspond to 140 90 mmHg measured in the office or clinic Table 5 ; . Give the patient clear instructions on the need to provide the doctor with proper documentation of the measured values and to avoid self-alterations of the treatment regimens and ddavp.
1. Bouquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, et al. Polychemotherapy in advanced non-small cell lung cancer: a metaanalysis. Lancet 1993; 342: 1921. Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F. Chemotherapy versus supportive care in advanced non-small cell lung cancer: results of a meta-analysis of the literature. Chest 1994; 106: 8615. Non-small Cell Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized trials. Br Med J 1995; 311: 899909. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992; 19: 64662. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277: 665. Schiff PB, Horwitz SB. Taxol stabilizes microtubles in mouse fibroblast cells. Proc Natl Acad Sci USA 1980; 77: 15615. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of taxol, nerbarone and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 85: 38894. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotuble agent. J Natl Cancer Inst 1990; 82: 124759. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, et al. Phase II study of taxol in patients with untreated advanced non-smallcell lung cancer. J Natl Cancer Inst 1993; 85: 3848. Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998; 5: 1087100. Huizing MT, Giaccone G, van Warmerdam LJ, Rosing H, Bakker PJ, Vermorken JB, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol 1997; 15: 31729. Kelly K, Crowley J, Bunn PA, Livingstone RB, Gandara DR. A randomized phase III trial of paclitaxel plus carboplatin PC ; versus vinorelbine plus cisplatin VC ; in untreated advanced non-small cell lung cancer NSCLC ; . A Southwest Oncology Group SWOG ; trial. Proc Soc Clin Oncol 1999; 18: 461a abstr 1777 ; . 13. Shiller JH, Harrington D, Sandler A, Belani C, Langer C, Krook J, et al. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer NSCLC ; . Proc Soc Clin Oncol 2000; 19: 1a abstr 2 ; . 14. Kosmidis P, Mylonakis N, Skarlos D, Samantas E, Dimopoulos M, Papadimitriou C, et al. Paclitaxel 175 mg m2 ; plus carboplatin 6 AUC ; versus paclitaxel 225 mg m2 ; plus carboplatin 6 AUC ; in advanced nonsmall-cell lung cancer NSCLC ; : a multicenter randomized trial. Ann Oncol 2000; 11: 799805. Tamura T, Sasaki Y, Nishiwaki Y, Saijo N. Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. Jpn J Cancer Res 1995; 86: 12039. Sekine I, Nishiwaki Y, Watanabe K, Yoneda S, Saijo N. Phase II study of 3 h infusion of paclitaxel in previously untreated non-small cell lung cancer. Clin Cancer Res 1996; 2: 9415.
Laboratory analytes were divided into 3 categories: hematology, chemistry including liver-derived ; , and urinalysis. Table 8 presents a summary of 60-month clinical laboratory data and stimate. Clopidogrel studyReassuringly the graph illustrates that virtually the majority of medical staff are aware of this policy. 21% increased awareness for Doctors 41% increased awareness for Nurses 20% increased awareness for Health Advisors 30% increased awareness for Counsellors. This comprehensive reference furnishes an overview of the subject from a historical, kinetic, and chemical context--providing a framework for drug metabolism in drug discovery and development and dexamethasone. MTF Pharmacy Scripts Mean 27.75 20.85 SD 31.05 28.07 Retail Pharmacy Scripts Mean 4.15 8.37 SD 13.11 18.48. Both ticlopidine and clopidogrel have been compared with aspirin in randomized controlled trials and both are approximately 10% more effective than aspirin and divalproex and clopidogrel. Regulating group assemblages of Dictyostelium slime mold, and the ability of plants to attract animal pollinators Andersson and Dobson, 2003; Atkinson et al., 2003; Guerrieri et al., 2002; LeVier et al., 2000; Newton and Fray, 2004; Ram et al., 1999; Town et al., 1976; Van Houdt et al., 2004 ; . Our data has shown that EDCs and pollutants block signaling between plants and bacteria necessary for establishing symbiotic nitrogen fixation, a process responsible for about 60% of the Earth's available nitrogen Lodwig et al., 2003 ; . Persistent pollutants and EDCs found in the soil pose a significant agricultural threat because their presence months to decades after application may result in long-term disruption of crucial symbiotic signaling. Compounds such as DDT and its metabolites DDD and DDE ; and PCBs persist in the soil environment today, although their use was banned in the United States in the 1970s. PCBs describe a class of biphenyl compounds with 210 chlorine substitutions that were commonly used as components of coolants, lubricants, and electrical equipment ATSDR, 2000 ; . PCBs are a commonly detected contaminant in groundwater, agricultural runoff, and soil in industrialized countries Alcock et al., 1998; Backe et al., 2004; Pedersen et al., 2003; Ritter et al., 2002 ; . PCBs inhibited NodDphytoestrogen signaling 1560% in a dose-dependent manner at concentrations ranging from 10 9 to Fig. 2 ; . DDT and its metabolites are found as contaminants in the soil and groundwater of agricultural regions where they were formerly used as insecticides. Recent findings of 972 ppb 3 M ; levels of total DDT and metabolites in agricultural soil in China led researchers to conclude that either degradation of these chemicals occurs at a slower rate than previously thought, or DDT may still be in use in some areas despite being banned for more than twenty years Gong et al., 2004 ; . Studies measuring DDT and its metabolites in the corn belt of the U.S. have reported mean levels of total DDT metabolites to be 10 ppb 29 nM ; with maximum levels of 11, 800 ppb 36 M ; Aigner et al., 1998 ; . The equivalent concentrations of DDT, DDD, or DDE tested in our assay resulted in a 10% and 45% reduction in NodD-phytoestrogen symbiotic signaling, respectively Fig. 2 ; . The soil environment contains plant material, bacteria, fungi, and an entire microcosm of organisms in constant molecular dialogue with one another and actively receiving and assimilating environmental cues. Pesticides and other environmental pollutants are directly and indirectly introduced into this complicated soil signaling network. In addition to pesticides and synthetic fertilizers that are routinely applied in vast quantities to agricultural fields, most crops are also irrigated with either treated or untreated wastewater Downs et al., 1999; Pedersen et al., 2003; Squillace et al., 2002 ; . A recent study detected the presence of over 130 different pesticides, plasticizers, pharmaceuticals, personal care products, and other pollutants in. The caprie 1996 ; study showed that plavix r ; clopidogrl ; and aspirin are quite toxic with over 50% of those who take either of them suffer from various toxic side effects and tolterodine. Guidelines used a Peto-Haybittle type rule based on the p value of the Mantel-Haenszel test. A twosided type 1 error of 0001 was used which preserved a type 1 error of 0048 for the end-ofstudy analysis. The results of interim analyses were to be disclosed to the Chairman of the Steering Committee only if the stopping rule was met. The quarterly External Safety and Efficacy Monitoring Committee reports also included a futility stopping rule based on the current 95% CI on the relative-risk reduction for the primary outcome cluster; the upper end of the interval had to exceed a 14% relative-risk reduction in favour of clopidogrdl compared with aspirin, otherwise the Steering Committee had to be informed. After each quarterly review, a report was sent to the chairman of the Steering Committee stating only that there was no reason not to continue the trial as planned. The Coordinating and Methods Centre at Hamilton facilitated and oversaw the study and provided methodological and administrative support to all committees, investigators, and other study personnel. Regional Data Collection Centres were at Hamilton, responsible for all the Canadian centres, and in affiliates of industrial backers--one in the USA and two in Europe. Assignment The Independent Statistical Centre provided computer-generated balanced blocks of four treatments with random allocation to clopifogrel or aspirin, stratified by clinical centre and the three disease subgroups. Access to this code was restricted to the Independent Statistical Centre, the Chairman of the External Safety and Efficacy Monitoring Committee, and to two independent companies responsible for preparing the study drugs. A copy of the randomisation scheme was deposited with a public notary. Blinding Patients were allocated study drugs sequentially from supplies at the clinical centre packaged in a predetermined order in a carton that contained supplies for four patients. These supplies were in the form of blister packs containing either 75 mg tablets of clopidogrel plus aspirin placebo tablets or 325 mg aspirin tablets plus clopidogrel placebo. Aspirin plus esomeprazole is superior to clopidogrel in the prevention of recurrent ulcer bleeding, according to the results of a study involving patients prescribed aspirin to prevent vascular diseases. 320 patients who presented with ulcer bleeds were successfully treated and, if negative for H. pylori, were randomised to clopidogrel 75mg daily n 161 ; or aspirin 80 mg daily plus esomeprazole 20 mg twice daily n 159 ; for one year. Recurrent ulcer bleeding occurred in 13 patients on clopidogrel and one on aspirin plus esomeprazole. The cumulative incidence of recurrent bleeding was 8.6% [95% CI, 4.1 to 13.1] in the clopidogrel group and 0.7% [0 to 2.0] in the group on aspirin plus. Drugs with a narrow therapeutic index represent the greatest concern e, g. Clopidogrel for high atherothrombotic risk and ischemic stabilization management and avoidance20 Connolly S, Pogue J, Hart RG, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events ACTIVE W ; : a randomised controlled trial. Lancet 2006; 367: 1903-1912. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004; 141: 745-752. Oden A, Fahlen M, Hart RG. Optimal INR for the prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res 2006; 117: 493499. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005; 36: 1588-1593. Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based casecontrol study. BMJ 2006; 333: 726. Paciaroni M, Agnelli G, Caso V, et al. Atrial fibrillation in patients with firstever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. J Thromb Haemost 2005; 3: 1218-1223. O'Donnell M, Oczkowski W, Fang J, et al. Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study. Lancet Neurol 2006; 5: 749-754. Deplanque D, Leys D, Parnetti L, et al. Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. Br J Clin Pharmacol 2004; 57: 798-806. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation: the verdict is in. Card Electrophysiol Rev 2003; 7: 374-378. Gage BF, Fihn SD, White RH. Warfarin therapy for an octogenarian who has atrial fibrillation. Ann Intern Med 2001; 134: 465-474. Kagansky N, Knobler H, Rimon E, et al. Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med 2004; 164: 2044-2050. Lip GY, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Chest 2006; 130: 1823-1827. Carrozza JP. Duration of clopidogrel therapy with drug-eluting stents. J Intervent Cardiol 2006; 19 5 Suppl ; : s40-s45. 33 Smith SC, Feldman TE, Hirshfeld JW. ACC AHA SCAI 2005 guideline update for percutaneous coronary intervention-summary article. A report of the American College of Cardiology American Heart Association Task Force on practice guidelines ACC AHA SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention ; . J Coll Cardiol 2006; 47: 216-235. Example: In the CURE study, the absolute risk of the primary endpoint in the clopidogrel plus aspirin combination ; therapy group was 9.3% and in the aspirin alone group was 11.4. Studies of platelet reactivity have established that there is substantial variability in the functional response to clopidogrel between individuals, regardless of dose. Clopidogrel more for health professionalsWe thank E.L. Beall, D.B. Roth, and members of the laboratory for critical reading of the manuscript and C.A. Gross and S. Nakamura for strains. This work was supported by National Institutes of Health grant GM31657 and National Institute on Environmental Health Sciences grant ESO1896. E.L.Z. is a Special Fellow of the Leukemia Society of America. The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked ``advertisement'' in accordance with 18 USC section 1734 solely to indicate this fact. Radiation Therapy Radiation therapy is performed under the care of a Radiation Oncologist or neurosurgeon typically after surgery or in cases where surgery is not an option due to the location or size of the brain tumor. The tumor and a small margin are usually targeted by a powerful beam of radiation. The radiation disrupts the DNA of the cells that are reproducing. Tumor cells reproduce much more often than normal brain cells, so they are affected more than normal cells. Normal cells are also better able to repair the damage from the radiation than tumor cells. We take advantage of this by breaking up the course of radiation into a number of smaller treatments instead of 1 big treatment except for a special form of radiation called "stereotactic radiosurgery" see below ; . This is called "fractionation", and gives the normal cells time to repair themselves, but not enough time for the tumor cells to repair themselves between treatments. A typical course of radiation involves a few minutes of treatment 5 times a week for 6 weeks. It has been shown that adding the oral chemotherapy drug, Temodar, to radiation makes the radiation work much better. Ask your doctor about it. Side effects of radiation can range from mild to severe and include skin burning and peeling, swelling edema ; , diarrhea and nerve damage. There are many types of radiation: Whole Brain Radiation: Radiation is applied to the entire brain. This is usually only used when there are multiple tumors, especially with metastatic brain tumors. In the past, it was used for all brain tumors, but more focused forms of radiation are now usually used. The cyphertm : 2002 ; sirolimus-eluting coronary stent ; is an expandable, slotted, stainless steel tube, with a drug sirolimus ; contained within a thin polymer coating on its surfaces. REFERENCES 1. 2. 3. Antithrombotic Trialists' Collaboration. BMJ 2002; 324: 71-86 Eccles M et al. BMJ 1998; 316: 1303-9 Sorensen HT et al. J Gastroenterol 2000 ; 95 : 2218-24 Which prophylactic aspirin? DTB 1997; 35: 7-8 Diener HC, Cunha L, Forbes C et al. European Stroke Prevention Study. 2 Dipyridamole and acetylsalicyclic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13 The SPS2 Group. European Stroke Prevention Study 2. Efficacy and safety data. J Neurol Sci 1996 ; 151 : S1-77 7. Prescribing antiplatelet drugs in primary care. MeReC Briefing. July 2005 8. NICE. Clopidogrel and modified-release dipyridamole in the prevention of occlusive events. Technology Appraisal 2005; 90: 1-34 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events CAPRIE ; . Lancet 1996; 348: 132939 Chan FKL, Ching JYL, Hung LCT et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Eng J Med; 352: 238-44 11. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004; 328: 434-7 The CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Eng J Med 2001; 345: 494-502 Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent stroke or transient ischaemic attack in high-risk patients MATCH ; : ranodmised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-7 NICE. Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome. Technology appraisal 2004; 80: 1-24 Clarification published 13.10.05 ; 15. COMMIT collaborative group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo controlled trial. Lancet 2005; 366: 1607-1617. Mc Allister HA, Fenoglio JJ. Tumors of the cardiovascular system. In: Mc Allister HA, Fenoglio JJ, editors. Atlas of Tumor Pathology. Washington DC: Armed Forces Institute of Pathology, 1978: 20-5. 2. Ryan PE Jr, Obeid AI, Parker FB Jr. Primary cardiac valve tumors. J Heart Valve Dis 1995; 4: 222-6. Salcedo EE, Cohen GI, White RD, Davison MB. Cardiac tumors: diagnosis and management. Curr Probl Cardiol 1992; 17: 73-137. Cardiogenic brain embolism. Cerebral Embolism Task Force. Arch Neurol 1986; 43: 71-84. Muir KW, McNeish I, Grosset DG, Metcalfe M. Visualization of cardiac emboli from mitral valve papillary fibroelastoma. Stroke 1996; 27: 1133-4. Graca A, Nunes R, Costeira A, Almeida J, Bastos P. Cardiac papillary fibroelastoma of a mitral valve chordae revealed by stroke. Rev Port Cardiol 1999; 18: 937-9. Giuliani ER, Gersh BJ, McGoon MD, Hayes DL, Schaff HV. Mayo Clinic Pratice of Cardiology. Third ed. New York: Mosby, 1996. 8. Grinda JM, Couetil JP, Chauvaud S, et al. Cardiac valve papillary fibroelastoma: surgical excision for revealed or potential embolization. J Thorac Cardiovasc Surg 1999; 117: 106-10. Lichtenstein HL, Lee JC, Stewart S. Papillary tumor of the heart: incidental finding at surgery. Hum Pathol 1979; 10: 473-5. Shahian DM, Labib SB, Chang G. Cardiac papillary fibroelastoma. Ann Thorac Surg 1995; 59: 538-41. Klarich KW, Enriquez-Sarano M, Gura GM, Edwards WD, Tajik AJ, Seward JB. Papillary fibroelastoma: echocardiographic characteristics for diagnosis and pathologic correlation. J Coll Cardiol 1997; 30: 784-90. Hicks KA, Kovach JA, Frishberg DP, Wiley TM, Gurczak PB, Vernalis MN. Echocardiographic evaluation of papillary fibroelastoma: a case report and review of the literature. J Soc Echocardiogr 1996; 9: 353-60. Mann J, Parker DJ. Papillary fibroelastoma of the mitral valve: a rare cause of transient neurological deficits. Br Heart J 1994; 71: 6. Daniel WG, Mugge A. Transesophageal echocardiography. N Engl J Med 1995; 332: 1268-79. Grote J, Mugge A, Schfers HJ, Daniel WG, Lichtlen PR. Multiplane transoesophageal echocardiography detection of a papillary fibroelastoma of the aortic valve causing myocardial infarction. Eur Heart J 1995; 16: 426-9. Giannesini C, Kubis N, N'Guyen A, Wassef M, Mikol J, Woimant F. Cardiac papillary fibroelastoma: A rare cause of ischemic stroke in the young. Cerebrovasc Dis 1999; 9: 45-9. Etienne Y, Jobic Y, Houel JF, et al. Papillary fibroelastoma of the aortic valve with myocardial infarction: echocardiographic diagnosis and surgical excision. Heart J 1994; 127: 443-5. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339: 1665-71. Yeh SP, Hsueh EJ, Wu H, Wang YC. Ticlopidine-associated aplastic anemia. A case report and review of literature. Ann Hematol 1998; 76: 87-90. Kao TW, Hung CC, Chen YC, Tien HF. Ticlopidine-induced aplastic anemia: report of three Chinese patients and review of the literature. Acta Haematol 1997; 98: 211-3. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events CAPRIE ; . CAPRIE Steering Committee. Lancet 1996; 348: 1329-39. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, Investigators of Doubleblind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study CLASSICS ; [In Process Citation]. Circulation 2000; 102: 624-9. Estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245 Ramos Ramos JC, Sanz Moreno J, Calvo Carrasco L, Garcia Diaz Jde D. Clopidogrel-induced hepatotoxicity. Med Clin Barc ; 2003; 120: 156-157 Duran Quintana JA, Jimenez Saenz M, Montero AR, Gutierrez MH. Clopidogrel probably induced hepatic toxicity. Med Clin Barc ; 2002; 119: 37 Willens HJ. Clopidogrel-induced mixed hepatocellular and cholestatic liver injury. J Ther 2000; 7: 317-318 Yeung E, Wong FS, Wanless IR, Shiota K, Guindi M, Joshi S, Gardiner G. Ramipril-associated hepatotoxicity. Arch Pathol Lab Med 2003; 127: 1493-1497 Fry SW, Seeff LB. Hepatotoxicity of analgesics and antiinflammatory agents. Gastroenterol Clin North 1995; 24.
Monday, january 24, 200 improve the overall health of your stomach in 4 weeks. Classics clopidogrel trialEtiology fever, corneal topography information, heart right chest, sacred heart rehab in memphis mi and efferent nerve signals to the arm. Essential kennel design, fibromyalgia 5-htp, clavicle what type of bone and family history groups or raptiva side effects. What is clopidogrel tellClopidogrel study, clopidogrel for high atherothrombotic risk and ischemic stabilization management and avoidance, clopidogrel more for health professionals, classics clopidogrel trial and what is clopidogrel tell. Plavix clopidogrel heart attack, clopidogrel oral, clopidogrel versus aspirin in patients at risk of ischaemic events and clopidogrel platelet function test or atrial fibrillation clopidogrel trial with irbesartan.
© 2009 |
